Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Crestor on Lipoprotein Metabolism in Humans

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Atlanta Research and Education Foundation
ClinicalTrials.gov Identifier:
NCT00214617
First received: September 19, 2005
Last updated: September 22, 2006
Last verified: September 2006

September 19, 2005
September 22, 2006
January 2005
Not Provided
  • Rate of production of VLDL apoB
  • Rate of clearance of VLDL apoB
  • Rate of production of LDL apoB
  • Rate of clearance of LDL apoB
Same as current
Complete list of historical versions of study NCT00214617 on ClinicalTrials.gov Archive Site
  • Rate of production of HDL apoA-I
  • Rate of clearance of HDL apoA-I
  • Activity of cholesteryl ester transfer protein
Same as current
Not Provided
Not Provided
 
Effect of Crestor on Lipoprotein Metabolism in Humans
Effect of Crestor on the Kinetics of Plasma Apolipoproteins: Dose-Response Study

The objective of this research is to understand how Crestor can effectively reduce the levels of the bad cholesterol, LDL, in blood. It is hypothesized that with a low dose, Crestor will facilitate the rate of removal of LDL from the blood. At the higher dose, the increased potency of Crestor is explained by a reduction in the production of LDL by the liver.

Crestor has been demonstrated to be effective in reducing plasma LDL by 20 to 60% in a dose dependent fashion. While the primary mechanism of action of this class of agents is the increase in the expression of LDL receptor resulting in accelerated clearance of LDL, the increase potency of Crestor in comparison to other statins may suggest other mechanisms. We propose to study the rate of incorporation of deuterated labeled leucine into VLDL apoB and LDL apoB and to determine the effect of two doses of Crestor (5 mg/day and 40 mg/day) on the production and clearance of apoB. Participants will be admitted to the General Clinical Research Center on three occasions (4 days, 3 nights per admission) for these metabolic studies. This is an open-label study design to reflect usual care with the first admission taking place while the participant is not on any lipid-lowering therapy. The second admission will occur after a minimum of 6 weeks on the low dose (5mg/day). The dose will be increased to 40 mg/day at the time of discharge and the third admission will occur after a minimum of 6 weeks on the higher dose.

A secondary objective of this study is to examine the rate of production and clearance of apoA-I, the major protein in HDL, at the 2 doses of Crestor. In addition to a reduction in LDL, Crestor has also been reported to result in a characteristic dose-dependent increase in HDL. The mechanism of this increase is not understood.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypercholesterolemia
Drug: Rosuvastatin at 5 mg/day and 40 mg/day
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
February 2006
Not Provided

Inclusion Criteria:

. TG between 200 and 400 mg/dL

  • LDLc between 160 and 250 mg/dL
  • HDLc between 30 and 50 mg/dL for men and 40-65 mg/dL for women
  • Lp(a) less than 30 mg/dL
  • Age between 50 and 75 years

Exclusion Criteria:

  • current lipid-lowering therapy,
  • primary hypertriglyceridemia (TG>400 mg/dL),
  • High HDL (HDL>70),
  • high Lp(a), greater than 30 mg/dL
  • presence of beta-VLDL on agarose electrophoresis,
  • current use of immunosuppressive agents,
  • hormone replacement therapy for women
  • history of cancer, active liver disease or hepatic dysfunction (AST or ALT 1.5 x ULN (Upper Limit of Normal),
  • excessive consumption of alcohol, and recent history of drug abuse.
Both
50 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00214617
AREF_Le_IRUSROSU 0021, IRUSROSU 0021
Not Provided
Not Provided
Atlanta Research and Education Foundation
AstraZeneca
Principal Investigator: Anh Le, PhD Emory University School of Medicine and Atlanta VAMC
Atlanta Research and Education Foundation
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP